Status:
UNKNOWN
Fecal Transplant for Alopecia Areata
Lead Sponsor:
Tel-Aviv Sourasky Medical Center
Conditions:
Alopecia Areata
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
the investigators intend to analyze the microbiome in the diseased areas, healthy skin and fecal samples. In addition, the investigators plan to evaluate how the fecal transplant can influence the sev...
Detailed Description
Alopecia areata (AA) is a common autoimmune disease that triggers non scarring hair loss in different severities. Usually the hair loss will be contained to the scalp and / or beard, but in some cases...
Eligibility Criteria
Inclusion
- AA patients with:
- Acute disease that appeared in the last 3 months.
- Recurrence of AA in the last 3 months, in a patient who had remission for at least one year.
- At least one patch of hair loss on the scalp and / or the beard, or with a widespread disease such as total loss of the hair over the entire scalp (alopecia totalis).
- In case of a single alopetic patch, the patch must be equal or bigger than 2 cm in diameter.
- All patients will be diagnosed by two separate dermatologist, or one dermatologist with the support of classical finding on skin biopsy.
Exclusion
- Patients who were treated with systemic corticosteroids / corticosteroids injection one year prior the study.
- Patients who were treated with topical corticosteroids two weeks prior the study.
- Patients who were treated with immunosuppressing medications or biological treatments one year prior the study.
- Patients who were treated with systemic antibiotics of any kind 3 months prior the study.
- Patient who were treated with topical antibiotics one months prior the study.
- Patients who were treated with probiotics one months prior the study.
- Patients with alopecia universalis (total loss of all body, scalp and facial hair).
- Patients with bowel disease or an active infection including clostridium difficile.
- Pregnant and breastfeeding women.
- Childrenbelow the age of 18.
- Malignant disease in the past 5 years.
- Patient with any infectious disease that require antibiotics during the study period.
- In any case a patient would like to withdraw from the study, for any reason, all samples will be destroyed immediately, and the patient will stop his participant in the study.
Key Trial Info
Start Date :
May 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2025
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT04833179
Start Date
May 1 2021
End Date
April 1 2025
Last Update
April 6 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.